clinical trial · NCT06389526
A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
Advanced or Metastatic Solid TumorsCHS-1000Toripalimab
brief summary
The primary purpose of this trial is to assess the tolerability and safety of CHS-1000 alone and in combination with toripalimab-tpzi in participants with advanced solid tumors.
started
Feb 15, 2025
primary completion
May 30, 2028
completion
May 30, 2028
last updated
Sep 19, 2024
official title
A Phase 1, Multicenter, Open-Label Study of CHS-1000 as a Single Agent and in Combination With Toripalimab-tpzi in Participants With Advanced or Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol